These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

612 related articles for article (PubMed ID: 17669558)

  • 1. Phencyclidine animal models of schizophrenia: approaches from abnormality of glutamatergic neurotransmission and neurodevelopment.
    Mouri A; Noda Y; Enomoto T; Nabeshima T
    Neurochem Int; 2007; 51(2-4):173-84. PubMed ID: 17669558
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phencyclidine and genetic animal models of schizophrenia developed in relation to the glutamate hypothesis.
    Enomoto T; Noda Y; Nabeshima T
    Methods Find Exp Clin Pharmacol; 2007 May; 29(4):291-301. PubMed ID: 17609743
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Animal model of schizophrenia: dysfunction of NMDA receptor-signaling in mice following withdrawal from repeated administration of phencyclidine.
    Nabeshima T; Mouri A; Murai R; Noda Y
    Ann N Y Acad Sci; 2006 Nov; 1086():160-8. PubMed ID: 17185514
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions.
    Javitt DC
    Int Rev Neurobiol; 2007; 78():69-108. PubMed ID: 17349858
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypofunctional glutamatergic neurotransmission in the prefrontal cortex is involved in the emotional deficit induced by repeated treatment with phencyclidine in mice: implications for abnormalities of glutamate release and NMDA-CaMKII signaling.
    Murai R; Noda Y; Matsui K; Kamei H; Mouri A; Matsuba K; Nitta A; Furukawa H; Nabeshima T
    Behav Brain Res; 2007 Jun; 180(2):152-60. PubMed ID: 17451820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Neuropsychopharmacological study on an animal model for negative symptom of schizophrenia induced by repeated phencyclidine treatment].
    Noda Y; Nabeshima T
    Yakugaku Zasshi; 2000 Aug; 120(8):677-82. PubMed ID: 10946617
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Baseline temperature in an animal model of schizophrenia: long-term effects of perinatal phencyclidine administration.
    Radonjić NV; Petronijević ND; Vucković SM; Prostran MS; Nesić ZI; Todorović VR; Paunović VR
    Physiol Behav; 2008 Feb; 93(3):437-43. PubMed ID: 17996259
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Involvement of a dysfunctional dopamine-D1/N-methyl-d-aspartate-NR1 and Ca2+/calmodulin-dependent protein kinase II pathway in the impairment of latent learning in a model of schizophrenia induced by phencyclidine.
    Mouri A; Noda Y; Noda A; Nakamura T; Tokura T; Yura Y; Nitta A; Furukawa H; Nabeshima T
    Mol Pharmacol; 2007 Jun; 71(6):1598-609. PubMed ID: 17344353
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of postnatal blockade of N-methyl-D-aspartate receptors on rat behavior: a search for a new developmental model of schizophrenia.
    Wedzony K; Fijal K; Mackowiak M; Chocyk A; Zajaczkowski W
    Neuroscience; 2008 Jun; 153(4):1370-9. PubMed ID: 18434025
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of NMDA receptor models of schizophrenia: divergences in the behavioral effects of sub-chronic PCP and MK-801.
    Seillier A; Giuffrida A
    Behav Brain Res; 2009 Dec; 204(2):410-5. PubMed ID: 19716985
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rapid cortico-limbic alterations in AMPA receptor densities after administration of PCP: implications for schizophrenia.
    Zavitsanou K; Nguyen V; Newell K; Ballantyne P; Huang XF
    J Chem Neuroanat; 2008 Oct; 36(2):71-6. PubMed ID: 18640263
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Excitatory and inhibitory neurotransmission is chronically altered following perinatal NMDA receptor blockade.
    du Bois TM; Deng C; Han M; Newell KA; Huang XF
    Eur Neuropsychopharmacol; 2009 Apr; 19(4):256-65. PubMed ID: 19150227
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glutamatergic neurotransmission modulation and the mechanisms of antipsychotic atypicality.
    Heresco-Levy U
    Prog Neuropsychopharmacol Biol Psychiatry; 2003 Oct; 27(7):1113-23. PubMed ID: 14642971
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Behavioral assessment of neuroleptics (3)--Schizophrenia negative symptoms-like model induced by PCP].
    Noda Y; Nabeshima T
    Nihon Shinkei Seishin Yakurigaku Zasshi; 1996 Aug; 16(4):123-8. PubMed ID: 8905801
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of the mGluR allosteric modulation in the NMDA-hypofunction model of schizophrenia.
    Doreulee N; Alania M; Mitaishvili E; Chikovani M; Chkhartishvili B
    Georgian Med News; 2009 Dec; (177):59-65. PubMed ID: 20090156
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prenatal exposure to PCP produces behavioral deficits accompanied by the overexpression of GLAST in the prefrontal cortex of postpubertal mice.
    Lu L; Mamiya T; Lu P; Toriumi K; Mouri A; Hiramatsu M; Zou LB; Nabeshima T
    Behav Brain Res; 2011 Jun; 220(1):132-9. PubMed ID: 21277907
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chronic infusion of PCP via osmotic mini-pumps: a new rodent model of cognitive deficit in schizophrenia characterized by impaired attentional set-shifting (ID/ED) performance.
    Pedersen CS; Goetghebeur P; Dias R
    J Neurosci Methods; 2009 Dec; 185(1):66-9. PubMed ID: 19761795
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Development of animal models for schizophrenia based on clinical evidence: expectation for psychiatrists].
    Noda Y; Mouri A; Waki Y; Nabeshima T
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2009 Apr; 29(2):47-53. PubMed ID: 19562941
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Glutaminergic hypothesis of schizophrenia: clinical research studies with ketamine].
    Mechri A; Saoud M; Khiari G; d'Amato T; Dalery J; Gaha L
    Encephale; 2001; 27(1):53-9. PubMed ID: 11294039
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A pharmacological model for psychosis based on N-methyl-D-aspartate receptor hypofunction: molecular, cellular, functional and behavioral abnormalities.
    Rujescu D; Bender A; Keck M; Hartmann AM; Ohl F; Raeder H; Giegling I; Genius J; McCarley RW; Möller HJ; Grunze H
    Biol Psychiatry; 2006 Apr; 59(8):721-9. PubMed ID: 16427029
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.